EE156 Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure (HF) with Preserved Ejection Fraction (HFPEF) in France, Based on Emperor-Preserved Clinical Trial
Abstract
Authors
P Levy N Lamblin H Groyer J Chollet J Tardu S Linden L Fauchier